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Many microbial antigens contain powerful hypervariable epitopes that fail to induce broadly protective immunity because
they dominate the immune response at the expense of more conserved but weaker epitopes. If the undesired B cell epitopes
are eliminated, the immune system could be focused on the conserved epitopes and produce a stronger antibody response
to conserved parts of the protein and thus become a more efficacious immunogen for a vaccine. We examined this possibility
using the human immunodeficiency virus envelope glycoprotein (gp)120 IIIB/LAI and selectively replaced the amino acids
from the V3 region and analyzed the overall immunogenicity of the mutant proteins after nucleic acid immunization in mice.
The most variable residues of the human immunodeficiency virus type 1 gp120 V3 loop sequence were replaced with serine,
which has a small uncharged hydrophilic side chain and therefore is likely to be less immunogenic than amino acids found
in wildtype V3 sequences. The serine substitutions did not affect the ability of soluble CD4 to bind the mutant molecules
compared with wildtype gp120 and monoclonal antibodies against both linear and discontinuous epitopes located in the
V1/V2, C1, and C4 regions of the molecule. These data suggest that the V3 loop substitutions did not grossly affect the overall
conformation of the envelope molecule. Immunization of CBA 3 BALB/c F1 mice with DNA expression plasmids for the
wild-type gp120 sequence induced a predominantly IgGI antibody response with end point titers of 10
4–5 3 104. The
antibodies reacted only with conformationally intact gp120. Serine replacements targeted to both sides of the V3 loop had
a major impact on gp120 immunogenicity, with a markedly reduced response in the majority of animals tested. Analysis of
the epitope specificity of the responses suggests that N-terminal amino acids in the V3 loop contribute to the major
immunodominant epitope and provides no evidence that their removal enhances immunogenicity of the conserved regions.
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INTRODUCTION
The envelope (env) glycoprotein of human immunode-
ficiency virus type 1 (HIV-1) is expressed as a gp160
precursor, which on proteolytic cleavage yields the ex-
tracellular and transmembrane proteins gp120 and gp41,
respectively. The envelope glycoprotein (gp) is responsi-
ble for interacting with cellular receptors (CD4 and co-
receptors including the CCR-5 and CXCR-4 chemokine
receptors) and for initiating fusion of the virus with the
cell membrane (Dimitrov, 1997). Furthermore, the env
glycoprotein is the major target for the neutralizing anti-
body response and therefore has been the focus for the
development of recombinant subunit vaccines (Cease
and Berzofsky, 1994).
The gp120 glycoprotein has five variable regions sep-
arated by more conserved regions (Kwong et al., 1998;
Modrow et al., 1987; Rizzuto et al., 1998; Simmonds et al.,
1990; Wyatt et al., 1998). Variations within gp120 occur
within HIV-infected individuals during replication of the
virus and pose a major problem for the generation of an
effective broadly reactive immune response. The third
variable (V3) region of gp120, which is immunodominant
in both infected humans and immunized animals (Moore
and Nara, 1991; Nara et al., 1990), has been defined as
one of the two principal neutralizing domains (Chamat et
al., 1992). Although the V3 region appears not to be
essential for the interaction with CD4 (Pollard et al.,
1992), it does contain sequences critical for the interac-
tion with chemokine receptors (Choe et al., 1996; Cocchi
et al., 1996; Oravecz et al., 1996; Rizzuto et al., 1998).
However, primary HIV-1 isolates are relatively insensitive
to V3-mediated neutralization; therefore, it might be de-
sirable to redirect the immune response away from the
V3 region and toward epitopes in the conserved regions
of gp120 (reviewed in Fenyo et al., 1996).
Although recent topographic analysis of gp120 sug-
gests that the hypervariable regions are accessible at
the surface of the molecule, there also are segments of
the conserved C1, C4, and C5 regions that are predicted
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to be surface exposed. The C4 region forms part of the
CD4 binding site, which is a target for neutralizing anti-
bodies (Kwong et al., 1998; Moore and Sodroski, 1996).
Extensive deletions in the env glycoprotein have been
made by others to examine aspects of the immunological
and biological properties of the proteins. Elimination of
the V1/V2, V3, and V4 variable regions results in trun-
cated proteins that maintain their ability to bind soluble
CD4 (sCD4) albeit with different affinities compared with
wildtype protein (Jeffs et al., 1996; McKeating et al., 1996;
Pollard et al., 1992; Wyatt et al., 1993). These truncated
proteins maintain their ability to interact with some neu-
tralizing antibodies; however, most of the epitopes that
dominate the truncated molecules are not accessible on
the intact gp120 molecule (Lu et al., 1998).
An alternative strategy to develop epitope-specific
molecules is based on the introduction of mutations,
which alters the immunogenicity of the targeted epitope.
We have previously shown using human chorionic go-
nadotropin b-chain as a model that it is possible to
change the antigenicity of proteins, and possibly their
immunogenicity, without losing key conformational
epitopes (Jackson et al., 1996). This was achieved by
selectively mutating amino acid residues with side
chains protruding from the molecule. In the present
study, we substituted the residues within the V3 region
for amino acids possessing short side chains to reduce
the immunogenicity. Jin et al. (1992) reported that rela-
tively few side chains are required to define an epitope
on human growth hormone, with the most critical amino
acids being arginine, then proline, and then equally glu-
tamic acid, aspartic acid, phenylalanine, and isoleucine.
Thus, serine possessing a small uncharged hydrophilic
side chain was chosen to substitute for V3 hypervariable
residues.
RESULTS
Construction of mutated gp120 V3 sequences
The strategy used to construct the V3 mutations is
schematically outlined in Fig. 1, where the highly con-
served sequence GPGR in the apex of the loop was
left unmodified. A unique SmaI site was introduced in
the GPGR sequence by a silent mutation, allowing the
combination of N- and C-terminally introduced muta-
tions of the V3 sequence. A BglII env fragment was
used as the template for the PCR-generated mutagen-
esis reactions. Several mutants were generated, of
which the three most extensive, gp120–4A, gp120–4C,
and gp120–4E (Fig. 1B), were selected for further anal-
ysis. gp120–4A has substituted 321AFVTIGKIGN330 with
321SSSSSSKSSS330 within the C-terminal side of the
GPGR sequence; gp120–4C has further substituted
312IRIQR316 with 312SSSSS316 on the N-terminal side of
the GPGR sequence; and gp120–4E is like gp120–4C
but with two of the N-terminal substituted serine res-
idues deleted because many primary V3 sequences
exhibit such deletions (LaRosa et al., 1991, and Los
Alamos database).
Antigenicity of Chinese hamster ovary-derived mutant
gp120 molecules
The wildtype and mutant plasmid were transfected
into Chinese hamster ovary (CHO) cells and selec-
tively amplified with methionine sulfoximine (MSX).
The levels of recombinant env proteins were 800 ng/ml
(wildtype protein), 1200 ng/ml (mutant gp120–4A), 940
ng/ml (mutant gp120–4C), and 880 ng/ml (mutant
gp120–4E). The wildtype and mutant gp120 IIIB/LAI
recombinant proteins synthesized comigrated as a
single band on SDS–PAGE, suggesting no major dif-
ferences in the apparent molecular weight or in the
stability of the proteins (Fig. 2). The effect of the
mutations on the conformation of the recombinant
gp120 was examined in a capture ELISA on plates
coated with polyclonal antiserum directed against the
C terminus of gp120. A number of monoclonal antibod-
ies (MAbs) directed to nonoverlapping linear or con-
formation-dependent epitopes were used (Table 1).
The MAbs 10/36e, 8/64b, 55/11, and 55/68b recogniz-
ing linear epitopes and ICR41 specific for a discontin-
uous epitope within V3 were affected by the serine
substitutions in the C-terminal portion of V3. The MAbs
10/54ow and 8/38c/1c recognize amino acids in the
N-terminal V3 region, which are affected by the serine
substitutions introduced in gp120–4C and gp120–4E
(Table 1). Only the V3-loop-specific MAb 55/45a/11,
recognizing a conformational determinant within V3, is
unaffected by the serine substitutions (Table 1).
All three mutants bound MAbs directed against the
C1, V2, and C4 regions of the molecule, with affinities
close to that seen with the wildtype molecule (Table 1).
None of the serine substitutions affected the confor-
mation of the CD4 binding site on the mutant molecule
because the CD4 binding-site-specific MAbs ICR39.13g
and 10/46c (Table 1), as well as soluble CD4-IgG (Fig.
3), reacted equally well with the mutants as with the
wildtype protein. Thus serine substitutions in the V3
loop do not appear to significantly affect the confor-
mation in the C1, V1/V2 loops, or discontinuous CD4
binding site.
To further probe for alterations in overall structure of
the gp120 molecule after V3 serine substitutions, we
selected five additional conformation-sensitive MAbs
recognizing epitopes distinct from the CD4 binding
site, V1, V2, and V3 regions, although the precise
location of the epitopes are unknown. As shown in Fig.
4, MAb 55/32 bound to the wildtype and all three
mutants equally well. However, serine substitutions in
both the N- and C-terminal V3 loop stem have a sig-
nificant effect on the binding of the remaining four
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MAbs, although not all to the same extent. The MAb
58/30 bound to gp120–4A and -4C to a slightly lesser
degree than seen with the wildtype but gave stronger
binding to gp120–4E. The remaining the MAbs (33/90,
35/75ow/4k, and 35/25/2b) showed reduced binding to
all three mutants. Because the binding affinity of these
three MAbs to all mutant gp120s appeared to be sim-
ilar, we cannot detect any differential effects of the
various serine substitutions in the V3 loop. Substitu-
tions in the N-terminal part of the V3 loop do not
appear to induce further conformational changes, al-
though shortening the V3 by two amino acid residues
may slightly affect the conformation by making some
epitopes, such as those recognized by MAbs 58/30,
more accessible.
Immunogenicity in mice of the gp120 mutants
Having established that the serine substitutions in the V3
loop do not grossly affect the overall conformation of the
HIV gp120 protein, we wanted to examine what effect they
might have on the immunogenicity of the molecule. To
reduce the influence of haplotype and mouse strain varia-
tion within these experiments, we used groups of 8 F1
(CBA/Ca 3 BALB/c) mice for each immunization. Immuni-
zation induced a range of antibody responses (Fig. 5) with
end point titers of 104 to 5 3 104. The gp120-specific anti-
bodies were predominantly of the IgG2a isotype (results not
shown), and reacted with native recombinant gp120 but not
with denatured antigen using the method of Moore and Ho
(1993) (results not shown).
FIG. 1. The construction of the gp120 V3 mutants. (A) Schematic outline of V3 mutant construction. (B) The amino acid sequence of wildtype and
mutant gp120 molecules.
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Mutant gp120–4A induced a gp120-specific antibody
response indistinguishable from that seen in mice
immunized with the wildtype gene (Fig. 5, left column).
However, substitutions with serines on both sides of
the V3 loop markedly affected the overall level of the
gp120-specific IgG response. Only two animals immu-
nized with the gp120–4C plasmid produced gp120-
specific IgG levels similar to that seen in wildtype
immunized mice, whereas the remaining six animals
exhibited $10-fold lower levels of gp120-specific IgG.
When the N-terminal region was shortened by two
amino acids (mutant gp120–4E), the immune response
appeared to be further reduced compared with mice
immunized with the wildtype gp120 gene. However,
four of the eight animals immunized with the gp120–4E
plasmid had appreciable levels of gp120-specific an-
tibodies with end point titers of ;104, as seen in the
wildtype immunized animals.
The data shown in Fig. 5 (left columns) were obtained
using baculovirus-derived wildtype gp120 as target anti-
gen. Because it is possible that conformational changes
induced by the serine substitutions had exposed or cre-
ated neoepitopes, the antibody levels against the appro-
priate CHO-derived mutant protein were also measured
(Fig. 5, right columns). The levels of the gp120-specific
IgG for gp120–4A and gp120–4C were not markedly dif-
ferent from those determined with baculovirus-derived
wildtype gp120. Only gp120–4E appeared to bind slightly
higher levels of IgG when the mutant molecule was used
as the target (P 5 0.0312, unpaired Student’s t test),
suggesting the presence of epitopes not accessible on
the wildtype protein.
The antisera were characterized for reactivity to differ-
ent parts of the gp120 molecule using 15 peptides con-
taining sequences from the C1, V1, V2, V3, C4, and C4/
V5/C5 regions of the env molecule representing 42% of
FIG. 2. Western blots of recombinant wildtype and mutant gp120 proteins probed with rabbit anti-gp120 polyclonal antiserum (ADP 421) and sheep
anti-gp120 C-terminal antiserum (D7324). Lane 1 shows 100 ng of baculovirus-derived gp120 IIIB/LAI; lane 2, serum-free medium; lane 3, medium from
CHO cells transfected with the control plasmid pEE6hCMV-GS; lane 4, wildtype plasmid; lane 5, mutant gp120–4E plasmid; lane 6, mutant gp120–4C
plasmid; lane 7, mutant gp120–4A plasmid; and lane 8, a plasmid containing a nonexpressed gp120 mutant. The level of recombinant protein in the
medium of the transfected CHO cells was 800 ng/ml for wildtype gp120, 940 ng/ml for gp120–4C, 880 ng/ml for gp120–4E, and 1200 ng/ml for
gp120–4A as quantified using a capture ELISA with a pool of human HIV-positive sera (QC256) (Shotton et al., 1995).
TABLE 1
Binding of MAbs (10 mg/ml) Specific for Linear (L) or Discontinuous (D) Epitopes Within C1, V2, V3, and CD4
Binding Site (CD4 bs) to CHO Cell Derived Recombinant gp120 Proteins
mAb Epitope gp120-wt gp120-4A gp120-4C gp120-4E
11/65a/5h C1 [D] 1.08 0.94 0.94 1.16
11/4c/1j/3j V2 [L] 1.61 1.55 1.49 1.53
11/68b V2 [D] 1.44 1.47 1.35 1.58
ICR39.13g CD4bs [D] 1.5 1.48 1.46 1.54
10/46c CD4bs [D] 1.24 1.32 1.27 1.33
ICR38.1a C4 [L] 1.58 1.52 1.57 1.57
10/36e V3 [L] 0.64 0.2 0.01 0.02
11/75a/21/41 V3 [D] 1.36 0.2 0.13 0.22
10/54ow/6i/6i V3 [L] 1.29 1.3 0.02 0.04
55/45a/1l V3 [D] 1.42 1.53 0.81 1.05
8/38/1c V3 [L] 1.23 1.22 0.01 0.06
8/64b V3 [L] 1.3 0.01 0.01 0.01
55/1l V3 [L] 1.56 0.01 0.01 0.01
55/68b V3 [L] 1.26 0.01 0.03 0.02
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the sequence of gp120 IIIB/LAI. Positive results were
obtained only with peptides containing sequences from
the V3, C1, and C-terminal region of the molecule. Par-
ticularly interesting is the result obtained with the V3
peptide (Fig. 6). Sera from six of seven responding mice
immunized with wildtype gp120 gene and five of the
seven responding mice immunized with mutant gp120–4A
had V3 loop-specific antibodies with end point titers of
the order of 104. This sharply contrasts with the response
obtained from immunization with mutants gp120–4C and
-4E, in which only two mice (both immunized with gp120–
4C) had V3-reactive IgG levels detectable above back-
ground. This implies that substitutions of serine residues
in the N-terminal part of the V3 loop dramatically reduce
the immunogenicity of this region and suggest that these
residues contribute to the immunodominant nature of the
V3 region.
DISCUSSION
The V3 loop of the HIV-1 gp120, which is a variable part
of the envelope protein (LaRosa et al., 1991), is exposed
on the infected cell and viral surface (Poignard et al.,
FIG. 3. Affinity of sCD4 for wildtype and mutant gp120 recombinant
proteins. Increasing concentrations of sCD4-Ig were allowed to react
with saturating concentrations of CHO cell-derived wildtype gp120 (M),
gp120–4A (L), gp120–4C (), and gp120–4E (E). The bound sCD4 was
detected with anti-CD4 MAb ADP359. The data represent a single
experiment, and each data point is the mean value of triplicate wells.
The SE was within 10% for all antibody–antigen combinations tested.
FIG. 4. Affinity of conformation-sensitive MAbs for wildtype and mutant gp120. Increasing concentrations of MAbs were reacted with saturating
concentrations of CHO cell-derived wildtype gp120 (M), gp120–4A (L), gp120–4C (), and gp120–4E (E) recombinant proteins.
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1996). It contains dominant B cell epitopes that can elicit
high levels of neutralizing antibodies, which unfortu-
nately are to some extent isolate dependent (see Poig-
nard et al., 1996). We describe an attempt to reduce the
overall immunogenicity of the V3 loop by substituting
several of the hypervariable residues with serine with the
hope that elimination of a dominant epitope in the HIV
env protein would enhance the immunogenicity of more
conserved regions of the protein. The mutants give some
additional detail about the env protein and provide fur-
ther insights into epitope competition, which is of gen-
eral interest in vaccine development.
Serine substitutions within the V3 loop induce
conformational changes
The serine substitutions did not affect the ability of
soluble CD4-IgG and MAbs against linear and discon-
tinuous epitopes located in the V1/V2, C1, and C4 regions
of the molecule to bind the mutant molecules compared
with wildtype gp120. This suggests that the V3 loop
substitutions do not grossly alter the overall conforma-
tion of the envelope molecule, which is consistent with
the observation that the V3 region can be deleted without
eliminating the ability of the truncated gp120 to bind
soluble CD4 (Jeffs et al., 1996; Pollard et al., 1992; Wyatt
et al., 1993) and with the recent crystal structure of gp120
(Kwong et al., 1998; Rizzuto et al., 1998; Wyatt et al., 1998).
However, some local structural changes were observed.
It is perhaps not surprising that the introduction of nine
serines into recombinant gp120–4A will induce some
conformational alterations. LaRosa et al. (1991) predicted
a selective pressure in conserving V3 structure with a
b-strand-b-turn-b-strand-coil with the conserved GPG
forming the b-turn structure. The C-terminal b-strand
FIG. 5. Immune response to wildtype and mutant gp120 after DNA immunization. CBAxBALB/c mice were immunized with 100 mg of pEE6hCMVGS
containing wildtype gp120 gene, gp120–4A gene, gp120–4C gene, or gp120–4E gene at weeks 0, 2, 4, and 6. Serum samples (diluted 1:100) were
tested in a sandwich ELISA with baculovirus-derived wildtype gp120 IIIB/LAI protein, wildtype gp120 IIIB/LAI protein derived from CHO cells, or the
corresponding CHO-derived mutant gp120 protein (i.e., the protein containing the mutant sequence encoded by the DNA immunogen). Each line
represents an individual mouse.
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consists mainly of hydrophobic residues, which could
contribute to the formation of the hydrophobic core, such
that replacement of these amino acids with serines,
containing a hydrophilic side chain that may also encode
a potential O-linked sugar site, could alter the structural
environment of the V3 loop to increase its surface ac-
cessibility. The C-terminal serine substitutions prevented
the binding of five V3-specific MAbs directed predomi-
nantly against linear epitopes (Table 1) because the
contact residues have been replaced with serines, be-
cause the substituting amino acids induced structural
changes affecting the antigen binding sites, or, if O-
linked glycosylated, because the carbohydrate chain
masks the epitopes. Replacement of residues 312IRIQR316
in the N-terminal part of the V3 loop introduces four and
three additional potential sites for O-linked glycosylation
in gp120–4C and gp120–4E, respectively. However, if
there was additional O-linked glycan modification on the
mutant gp120 molecules, it did not appear to affect the
mobility of the proteins in SDS–PAGE analysis (Fig. 2). In
addition, neither the amino acid substitutions nor any
putative additional carbohydrate structures on these
sites had any effect on the binding of the conformational
sensitive MAbs 58/30, 33/90, 35/25/2b, and 35/75ow/4k
(Fig. 4), but they did affect the binding of two V3-specific
MAbs recognizing linear epitopes (Table 1). It is, how-
ever, surprising to note that shortening of the N-terminal
loop by two residues (gp120–4E) appears to have a more
dramatic effect on gp120 conformation, as demonstrated
by the binding of MAbs 58/30, 30/90, and 35/25/2b (Fig.
4). These MAbs bind with greater affinity to gp120–4E
than to gp120–4A or gp120–4C. Indeed. the epitope rec-
ognized by 58/30 seems to be more exposed on
gp120–4E than on CHO-derived rgp120. In this context, it
is interesting to note that 234 of the 245 primary se-
quences reported by LaRosa et al. (1991) had a shorter
V3 loop, whereby amino acid residues 17 and 18 of the
loop of gp120 IIIB/LAI were absent, suggesting different
epitope exposure on these env proteins.
Effect of the mutants on immunogenicity
The substitutions and the conformational changes ob-
served in the CHO-derived gp120–4A molecule appeared
not to have a noticeable effect on the overall immuno-
genicity in mice. After DNA immunization, gp120–4A pro-
duced an immune response indistinguishable from that
obtained with the wildtype gp120. The sera titered out at
the same dilution when measured on baculovirus-de-
rived rgp120, on the appropriate CHO-derived protein,
and on the V3 peptide. In contrast, serine substitutions in
the N-terminal V3 region (mutant gp120–4C) did affect
the overall immune response to gp120–4C by reducing
the end point IgG titer by 10-fold and by almost eliminat-
ing V3-specific antibodies. The two mice with apprecia-
ble levels of gp120-specific antibodies also had V3-loop-
specific IgG levels detectable above background.
The difference in the immune response between
gp120–4A and gp120–4C clearly demonstrates that, as in
humans (Moore and Ho, 1993), the V3 region in mice is
FIG. 6. Epitope specificity of antibody responses from mice immunized with wildtype and mutant gp120 DNA. Log10 end point dilutions of
peptide-reactive IgG in sera from the DNA-immunized animals. The peptides used were V3 long (ADP729.3: CTRPNNNTRKSIRIQRG-
PGRAFVTIGKIGNMRQAHCN), C1 (ADP740.8: EQMHEDIISLWDQSLKPCVK), and C terminus (ADP710 VVKIEPLGVAPTKAKRRVVQRE).
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the most immunogenic region of gp120 because elimi-
nation of B cell epitopes within V3 reduces the overall
immune response. Because the serine substitutions of
residues 312IRIQR316, but not those in the C-terminal part
of V3 region, nearly completely eliminate this B cell
epitope, it must map to the N-terminal part of the loop
and include some amino acid residues with solvent pro-
truding side chains, which is consistent with the map-
ping of the epitopes using sera from other species.
However, shortening the V3 region by two amino acid
residues enhanced the exposure of the binding sites for
epitopes recognized by the conformational sensitive an-
tibodies 58/30, 30/90, and 35/35/2b. Because the sera
from gp120–4E-immunized mice had higher gp120-
specific IgG levels when assayed on the mutant mole-
cule relative to the wildtype protein, we assume that the
epitopes recognized by these MAbs are better exposed
to the immune system and may represent strong B cell
epitopes not as readily accessible on wildtype gp120
type IIIB. It is not known whether gp120–4E is capable of
inducing stronger or more strain-specific neutralizing
antibody responses. All the sera were tested for their
ability to neutralize infectivity of the infectious clone LAI
for both 8166 and SupT1 cells, but all sera failed to
neutralize at the highest concentrations of serum tested
(1:20 final dilution).
Two recent studies described the use of altered gly-
cosylation to refocus the epitopes of gp120. Garrity et al.
(1997) introduced putative glycosylation sequences into
the V3 region by site-specific mutagenesis. The mutant
genes were cloned into vaccinia virus vectors, which
were used to prime guinea pigs subsequently boosted
twice with the relevant recombinant protein in complete
Freund’s adjuvant. A mutant gp120 molecule, NL-1:2:3:4,
containing two putative new glycosylation sites in V3
(related to our mutant gp120–4C), elicited neutralizing
antibodies directed toward different epitopes than those
obtained after immunization with wildtype gp120. The
neutralization of the mutant antisera, but not that of the
wildtype sera, could be competed with the V1 peptide
131CTDLKNDTNTNSSSCRMIMEK151. Garrity et al. (1997)
therefore concluded that their mutations were able to
refocus the immune response to the V1 region as a
compensation for the loss of the immunodominant
epitopes present in the V3-loop. This appears to differ
from the conclusion drawn from our study, but there are
a several differences between our analysis and the study
of Garrity et al. (1997). First, we used DNA immunization,
which gives an antibody response with a different
epitope use than that observed after protein–adjuvant
immunization (Peet et al., 1997). Second, we were unable
to determine the level of neutralizing antibodies in our
sera and thus do not know whether our mutants could
induced an increased neutralization response. Third, be-
cause both the wildtype and mutant sera obtained by
Garrity et al. (1997) contained comparable levels of anti-
bodies specific for the V1 peptide, the change in the
neutralization epitope use could equally well be caused
by conformational changes induced by the amino acid
substitutions and glycosylation affecting the accessibility
of immunodominant epitopes not fully accessible in the
wildtype molecule as shown in our study. Finally, there
could be a species difference in the immune response
between mice and guinea pigs.
The ability of carbohydrate side chains to redirect the
immune response against gp120 was also demonstrated
by Reitter et al. (1998), who deleted three N-linked gly-
cosylation sites in the V1 region of SIV gp120 protein.
Rhesus monkeys infected with the mutant SIV exhibited
a markedly increased antibody response to a V1 peptide
and an enhanced neutralizing activity.
A more radical approach was used by Lu et al. (1998),
who deleted the V1–V2–V3 hypervariable regions in the
gp120, gp140, and gp160 env proteins of HIV-1 HXB-2 and
examined the immune response after DNA immunization of
rabbits. The sera from rabbits immunized with the nontrun-
cated form of the proteins reacted 10-fold less with the
truncated form of gp120 (dV123/gp120) molecule than with
the undeleted molecule, and the sera from rabbits immu-
nized with the truncated forms of the env proteins prefer-
entially recognized dV123/gp120 molecule over gp120. Fur-
thermore, the changes in the envelope proteins caused by
the deletion of the V1–V2–V3 regions also reduced the
ability of the molecules to elicit neutralizing antibodies.
Thus although truncation of V1–V2–V3 regions successfully
eliminates dominant epitope regions in the molecule, it
alters the conformation of the proteins too much to become
a suitable vaccine candidate.
Implications for vaccine design
For vaccine development, it is of great importance to
consider the mechanisms that determine the diversity of
the antibody response to a given vaccine candidate. The
phenomenon of “original antigenic sin” implies that an
individual challenged with a new immunogen largely
generates antibodies to related epitopes encountered on
an earlier antigen, at the expense of new epitopes. In
other words, in subsequent infections involving variant
antigens that bear additional highly immunogenic deter-
minants, the immune response may be dominated by
epitopes present on the original antigen to the detriment
of the new epitopes even if these are potentially very
powerful. It seems likely that the memory B cells already
bearing high-affinity antigen receptors will be preferen-
tially activated at the expense of naive B cells specific for
the new epitopes by successfully competing for the
available antigen and for space within the germinal cen-
ters. Presumably, a similar mechanism accounts for the
antigenic competition between different epitopes in the
primary immune response leading to antibody domi-
nance. Analysis of the immune response to IgG (Taussig,
66 PEET ET AL.
1971; Taussig and Lachmann, 1972), tobacco mosaic
virus protein (Benjamini et al., 1989), or synthetic pep-
tides (Ju et al., 1993) suggests that an epitope may
become dominant if there are either a larger number of
virgin B cells with surface IgM recognizing this epitope
or the epitope is recognized with greater affinity than
other epitopes on the antigen, thus giving relevant naive
B cells a proliferative advantage. Once primed, the dom-
inant B cells will selectively overshadow the immune
response.
We and others have argued that the elimination of
immunodominant hypervariable epitopes could redirect
the immune response toward less immunodominant con-
served epitopes (Coffin, 1986; Jackson et al., 1996; Roitt,
1989). However, the experiments presented here do not
appear to support this hypothesis because by eliminat-
ing the most immunodominant epitope on HIV-gp120
(mutant gp120–4C), the overall immune response to the
HIV-1 env protein was reduced 10-fold. It could be ar-
gued that the remaining epitopes might be inherently
weak and therefore still evoke a low, albeit enhanced,
antibody response. However, when tested with short
peptides from other parts of the molecule, C1, C4, and C
terminus, no elevated antibody levels were seen in the
sera from gp120–4C-immunized animals. The lack of
antigenic competition in the gp120 experiments could be
a consequence of the mode of antigen delivery because
the levels of antigen produced in DNA-immunized mice
are by nature very low and the mechanism for activation
of the immune response remains to be elucidated. It also
could be that the mutants have lost an important T helper
epitope from the V3 loop, the absence of which could
prevent an enhanced response occurring to the con-
served B cell epitope. This may be tested by immuniza-
tion with a construct containing the putative minimal V3
loop helper epitope attached to the mutant molecule.
MATERIALS AND METHODS
Antibodies and gp120
The MAbs used in the present study are listed in Table 2.
The baculovirus-derived recombinant HIV-1 IIIB gp120
(rgp120, clone BH10); the C1 peptides ADP740.7 (NFN-
MWKNDMVEQMHEDIISL) and ADP740.8 (EQMHEDIISL-
WDQSLKPCVK); the V1/V2 peptides ADP740.12 (SSS-
GRMIMEKGEIKNCSFNI), ADP740.13 (GEIKNCSFNISTSIR-
GKVQK), and ADP740.14 (STSIRGKVQKEYAFFYKLDI); the
V3 peptides ADP740.27 VEINCTRPNNNTRKSIRIQ),
ADP740.28 (NTRKSIRIQRGPGRAFVTIG), ADP740.29 (RG-
PGRAFVTIGKIGNMRQA), and ADP729.3 (CTRPNNNTRK-
SIRIQRGPGRAFVTIGKIGNMRQAHCN); the C4 peptides
ADP740.39 (DTITLPCRIKQIINMWQREVG) and ADP709
(NMWQEVGKAMYAPPISG); and the C4/V5/C5 peptides
ADP740.43 (LLLTRDGGNSNNESEIFRPG), ADP740.44
TABLE 2
Monoclonal Antibodies Used in the Analysis of the Antigenicity of Wildtype and Mutant gp120
mAb
Epitope
recognized
Amino acid
position Reference
8/19b/3e/41 Discontinuous Unpublished
8/38/1c V3 300–315 McKeating et al., 1992a
8/64b V3 300–315 McKeating et al., 1992a
10/36c/2j/51 V3 311–321 McKeating et al., 1992a
10/36e V3 311–321 McKeating et al., 1992a
10/46c CD4 binding site Discontinuous Unpublished
10/54ow/6i/6i V3 311–321 McKeating et al., 1992a
11/41a/4f C5 472–491 Unpublished
11/65a/5h C1 Discontinuous McKeating et al.,1993
11/68b V2 Discontinuous Shotton et al., 1995
11/4c/1j/3j V2 152–181 McKeating et al., 1993; Shotton et al., 1995
11/75a/21/41 V3 Discontinuous McKeating et al., 1992a
11/85b/14l/4l V3 311–321 McKeating et al., 1992a
30/90 Not determined Discontinuous Unpublished
35/25/2b Not determined Discontinuous Unpublished
35/75ow/4k Not determined Discontinuous Unpublished
55/11 V3 300–315 Unpublished
55/18 Not determined Discontinuous Unpublished
55/32/5d Not determined Discontinuous Unpublished
55/45a/11 V3 Discontinuous Unpublished
55/68b V3 300–315 Unpublished
58/30 Not determined Discontinuous Unpublished
ICR38.1a C4 427–436 Cordell et al., 1991; McKeating et al., 1992b;
McKeating et al., 1992c
ICR39.13g CD4 binding site Discontinuous Cordell et al., 1991; McKeating et al., 1992b;
McKeating et al., 1992c
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(NNESEIFRPGGGDMRDNWRS), ADP740.45 (GGDMRD-
NWRSELYKYKVVKI), and ADP710 (VVKIEPLGVAPTKAK-
RRVVQRE) were all obtained from the MRC-AIDS Di-
rected Program. The reactivities of the antisera were
also tested with a V1/V2 subfragment (McKeating et al.,
1996).
Construction of HIV-1 gp120 mutants
The 0.62-kb BglII fragment of HIV-1 gp120 type IIIB/LAV
containing the V1/V2 and V3 regions of the env protein
was isolated from pSP64gp120 (kindly provided from Dr.
P. Stephens, Celltech) and cloned into pSK1 modified to
contain a BglII site in the EcoRV site. The SmaI site was
eliminated by deleting the XbaI–SmaI part of the multiple
cloning sequence (MCS) region of the plasmid. Oligonu-
cleotide-directed site-specific mutagenesis (T7Gen,
UAB, Amersham, Berks, UK) was used to introduce an
unique SmaI site in the GPGR sequence in the tip of the
V3 loop by changing the proline codon from CCA to CCC.
Individual serine substitutions on either side of the GPGR
sequence in the V3-loop were introduced using PCR-
directed mutagenesis. After confirmation of the mutagen-
esis by sequencing, the V3-loop mutants gp120–4A,
gp120–4C, and gp120–4E were assembled using the
synthetic SmaI site in the GPGR sequence, and finally,
the BglII fragment of pEE6hCMVgp120GS (kindly pro-
vided by Dr. P. Stephens) was replaced with the serine-
substituted BglII fragments.
CHO cell transfection and gene amplification
Mycoplasma-free CHO cells were grown in GMEM-S
medium supplemented with 10% heat-inactivated fetal
calf serum (HIFCS), 0.5 mM L-glutamine, 50 units/ml
penicillin, and 50 units/ml streptomycin. Exponentially
growing CHO cells (5 3 106) were transfected with 30 mg
of plasmid DNA per flask using calcium phosphate co-
precipitation. At 24 h after transfection, the medium was
replaced with fresh GMEM-S containing 25 mM MSX.
The cells were incubated for 7–10 days until discrete foci
appeared. The medium and MSX were replaced once
during this period. The glutamine synthetase gene copy
number of individual foci was amplified by expanding
individual foci in medium containing 100–250 mM MSX.
SDS–gel electrophoresis
The transfected CHO cells were grown to ;80%
confluence in GMEM-S supplemented with 10% HIFCS
and MSX. The medium was replaced with serum-free
AIMV medium (Life Technologies Ltd., Paisley, UK) for
24 h, and then the supernatant was harvested, freeze-
dried, and reconstituted in 5% of the volume in PBS.
Aliquots of the supernatant were boiled in SDS–PAGE
sample buffer (100 mM Tris–HCl, pH 6.8, 2% SDS, 20%
glycerol, 20 mg/ml DTT), and the proteins were sepa-
rated on a 7.5% polyacrylamide gel according to the
method of Laemmli (1970). At the end of the electro-
phoresis, the gels were incubated in transfer buffer (25
mM Tris–HCl, 192 mM glycine, 20% methanol) and
electrophoretically transferred to Hybond-C extra
membranes (Amersham International, Amersham, UK).
After staining with 0.1% Ponceau-S in 5% acetic acid,
the membranes were blocked with 4% dried milk pow-
der (Marvel) in Tris–HCl-buffered saline containing
0.1% Tween 20. The blots were incubated with rabbit
gp120 antiserum (ADP421) in 4% Marvel (in Tris–HCl-
buffered saline containing 0.1% Tween 20) for 60 min.
After several washes in Tris–HCl-buffered saline con-
taining 0.1% Tween 20, the specific antibodies were
detected with goat anti-rabbit IgG using an enhanced
chemiluminescence (ECL) kit (Amersham) according
to the manufacturer’s instructions.
Nucleic acid immunization
Six-week-old female CBA/Ca 3 BALB/c (k 3 d haplo-
type) (n 5 8) mice were injected with 100 mg of bupiva-
caine (Astra Pharmaceuticals Ltd., Kings Langley, Herts,
UK) intramuscularly at 24 h before the injection of DNA.
Qiagen column (Qiagen Ltd., Dorking, Surrey, UK)-puri-
fied plasmid DNA, pEE6hCMVgp120GS containing either
wildtype or the mutated V3 sequences, or the control
plasmid pEE14 was dissolved in 154 mM NaCl at 1
mg/ml, and 100 ml of DNA was injected at weeks 0, 2, 4,
and 6 into the right soleus muscle of the mice. Then, 50
ml of blood was taken the day before each DNA injection,
and the mice were bled out 14 days after the last injec-
tion.
Anti-gp120 response
To measure the antibody response to gp120, Nunc
MaxisorpC microtiter plates were coated at 4°C over-
night with sheep anti-gp120 capture antibody (raised
against a peptide representing the C terminus of gp120;
D7324, Alto Bioreagents, Dublin, Eire) at 3 mg/ml with 100
ml/well in 0.05 M carbonate-bicarbonate buffer, pH 9.6, at
4°C for 16 h. The plates then were washed once in PBS
containing 0.05% Tween 20 (PBS-T), followed by blocking
with 200 ml of 10% heat-inactivated fetal calf serum in
PBS for 30–60 min at room temperature. Baculovirus
gp120 at 1 mg/ml in PBS-T containing 1% BSA (assay
buffer) was captured onto the plate at 37°C for 4 h. After
washing, 100 ml of mouse serum, diluted in assay buffer,
was added to each well and incubated for 16 h at 4°C.
After further washes, goat anti-mouse IgG–alkaline phos-
phatase conjugate (Sigma, Poole, UK) was added to
each well and incubated for 2 h at 37°C. After final
washes, 100 ml/well of 1 mg/ml p-nitrophenylphosphate
(Sigma) in 0.05 M carbonate-bicarbonate buffer, pH 9.6,
containing 2 mM MgCl2 was added to each well, and
when the positive control reached A410 5 ;0.8, the plate
was read using a Dynatech MR5000 ELISA plate reader.
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The sera from the immunized mice were also tested for
reactivity with a V1/V2 subfragment as described previ-
ously (McKeating et al., 1996).
The concentration of gp120 present in the CHO cell
supernatants was determined with a sandwich ELISA, as
described previously (McKeating et al., 1993), using re-
combinant gp120 (BH10 clone) as a reference standard.
A saturating amount of gp120 was allowed to bind to the
solid phase via antiserum D7324 at an input concentra-
tion of 500 ng/ml. Bound ligands were visualized with
either anti-rat Ig or anti-human Ig horseradish peroxi-
dase (SeraLabs, Crawley, UK), respectively, and TMB
substrate.
Antipeptide response
The antibody levels to individual linear peptides were
determined by ELISA. Peptides were coated directly onto
the solid support at 3 mg/ml in 0.05 M carbonate–bicar-
bonate buffer, pH 9.6, at 4°C for 16 h. The ELISA was
then carried out as described above. MAbs recognizing
individual peptides (Table 2) served as positive controls
to confirm the presence of the peptide, and their binding
was detected using a monoclonal mouse anti-rat light
chain alkaline phosphatase conjugate (Sigma) at a
1:2000 dilution.
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